NCT05458765View on ClinicalTrials.gov

Project Engage: Oral PrEP Acceptability

PHASE2CompletedINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

June 21, 2022

Primary Completion Date

December 13, 2023

Study Completion Date

July 25, 2024

Conditions
Acceptability of Health CareAdherence, Medication
Interventions
DRUG

emtricitabine/tenofovir alafenamide

200mg/25mg tablet, once daily dosing for 24 weeks

DRUG

Emtricitabine / Tenofovir Disoproxil Oral Tablet

200mg/300mg tablet, once daily dosing for 24 weeks

Trial Locations (3)

3201

CAPRISA Vulindlela, Pietermaritzburg

Unknown

MatCH Research Unit, Durban

Harare Health and Research Consortium (HHRC), Harare

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

CONRAD

OTHER

collaborator

FHI 360

OTHER

collaborator

United States Agency for International Development (USAID)

FED

collaborator

Gilead Sciences

INDUSTRY

lead

Eastern Virginia Medical School

OTHER

NCT05458765 - Project Engage: Oral PrEP Acceptability | Biotech Hunter | Biotech Hunter